Genetic and pharmacological studies have emphasised the role of serotonin 5-hydroxytryptamine (5-HT) as a possible etiologic factor in the development of attention-deficit hyperactivity disorder (ADHD). Tryptophan hydroxylase (TPH) is a rate-limiting enzyme in the biosynthesis of serotonin from tryptophan. Originally, the TPH gene was thought to be widely expressed, but a second form of TPH, TPH2, was recently identified and the TPH2 gene was found to be solely expressed in the brain. We examined eight single nucleotide polymorphisms (SNP) in the TPH2 gene for association with ADHD in 179 Irish nuclear families. Transmission disequilibrium test analysis revealed significant association between the T allele of marker rs1843809 with the disorder (v 2 ¼ 12.2, P ¼ 0.0006, OR ¼ 2.36). Stratifying data by the sex of the transmitting parent showed that this association was enhanced when paternal transmission was considered (OR ¼ 3.7). In addition, several haplotypes (all including the associated marker) were associated with ADHD. These preliminary findings suggest that TPH2 is a susceptibility locus for ADHD. Further confirmation, preferably from different ethnic groups, is required to firmly implicate TPH2 in the pathophysiology of ADHD. Molecular Psychiatry ( Keywords: attention-deficit hyperactivity disorder (ADHD); tryptophan hydroxylase (TPH2); transmission disequilibrium test (TDT); serotonergic system, genetic association Attention-deficit hyperactivity disorder (ADHD) is a common neurological disorder affecting 3-6% of children worldwide.
Attention-deficit hyperactivity disorder (ADHD) is a common neurological disorder affecting 3-6% of children worldwide. 1 It is one of the most common causes of referrals in family practice, paediatric neurology and child psychiatry. 2 Children can be diagnosed with ADHD as early as 5 years of age with males being more affected than females (ratio ranging from 3 : 1-9 : 1). Major symptoms of ADHD include inability to sustain attention, hyperactivity, impulsivity and aggressive behaviour. The consequences are devastating for family and peer relations as well as academic life. Behaviour at home and at school is disrupted and ADHD children have poor school performance compared to healthy and age-matched children. 1 Symptoms persist into adulthood in at least 30% of cases. The disorder is clinically heterogeneous and its aetiology remains unknown. However, several lines of evidence have implicated genetic and environmental factors as predisposing to the disorder. Heritability of ADHD is estimated to be between 70 and 90%. 3, 4 Environmental factors such as low birth weight, delivery complications, alcohol consumption and smoking during pregnancy, environmental toxins and diet are all implicated. 5 Serotonin 5-hydroxytryptamine (5-HT) is a neurotransmitter involved in a variety of functions such as attention, sleep, memory and learning, locomotion, control of appetite, anxiety and drug abuse. 6 Reduction in serotonergic function has been linked to ADHD symptoms such as aggression and impulsivity. 6, 7 In addition, recent pharmacological evidence supports the potential involvement of serotonergic system in the aetiology of ADHD. Administration of fluoxetine (a selective serotonin reuptake inhibitor) was found to reduce the hyperactivity produced by knocking out the dopamine transporter gene (DAT-KO) in mice and had no effect on wild-type animals. Furthermore, when DAT-KO mice were treated with 5-HT or with the dietary 5-HT precursor (L-tryptophan), hyperactivity was significantly reduced. These findings demonstrate the importance of 5-HT in relation to the hyperactivity observed in DAT-KO mice. 8 Although the exact mechanism is not well characterised, measurement of the extracellular dopamine in the striatum revealed no significant differences between DAT-KO and wild-type animals. These findings indicate that 5-HT can modulate hyperactivity of DAT-KO mice with no obvious change in the extracellular striatal dopamine level.
Until recently it was thought that only one form of TPH existed; however, TPH knockout studies in mice (mice Tph À/À) showed normal levels of 5-HT in certain brain regions compared to their wild-type siblings (Tph þ / þ ). These knockout mice also showed no significant differences in 5-HT-related behaviours. 10 The TphÀ/À mice did, however, show almost no evidence of 5-HT in the duodenum and in whole blood samples. Further investigation identified two Tph mRNA species, arising from different promoters and having different translational efficiencies indicating the presence of a second TPH gene. TPH1 was mapped to 11p15.2 and TPH2 was recently mapped to chromosome 12q15. The two isoforms are highly homologous having 71% amino-acid (aa) identities. In mice, TPH2 expression is detected solely in the brain, whereas TPH1 is expressed in the pineal gland, spleen, gut and thymus. 10 Similar patterns of THP2 expression have also been recently confirmed in humans. 11 The TPH2 gene is a fairly large gene of B93.6 kb with 11 exons flanked by 10 introns and is mapped to chromosome 12q21.1 (http://www.ensembl.org/Homo_sapiens/geneview? gene ¼ ENSG00000139287).
For the reasons described above, TPH2 variants affecting the synthesis and brain concentration of 5-HT might be associated with ADHD. We are not aware of any studies examining TPH2 variants in relation to ADHD. Recently, Tang et al 12 examined 69 ADHD trios for possible association with an A218C variant in intron 7 of the TPH1 gene in the Chinese Han population with no success. However, a study by Li et al 13 observed a haplotype of A218C and A-6526G variants associated with ADHD and learning disability (w 2 ¼ 9.362, df ¼ 3, P ¼ 0.025). The results of these studies are difficult to interpret, as TPH1 is not expressed in the brain. In the present study, we have genotyped variants covering the TPH2 gene with an average spacing of B7-10 kb in 179 Irish ADHD nuclear families.
Materials and methods

Subjects
In all, 179 Irish ADHD nuclear families were ascertained and diagnosed as described previously in Kirley et al 14 and outlined below. Families with clinically diagnosed ADHD children were recruited from child guidance clinics and ADHD support groups around Ireland. The age range of the probands was between 5 and 14 years, with males accounting for 88% of the cases.
To establish DSM-IV diagnoses, one or both parents were interviewed using the Child and Adolescent Psychiatric Assessment (CAPA). 15 To fulfil DSM-IV ADHD criteria for symptom pervasiveness, information about ADHD symptoms at school was obtained from teachers using a semistructured teacher telephone interview, 16 which involved asking the teacher about DSM-IV symptoms of ADHD and impairment shown in class. ADHD diagnostic subtypes were derived from DSM-IV diagnostic classification (Combined, Inattentive and Hyperactive-impulsive types). Symptom dimensions as well as comorbid disorders such as Oppositional Defiant Disorder (ODD) and Conduct Disorder (CD) were obtained from the Child and Adolescent Psychiatric Assessment (CAPA). A positive family history of ADHD was defined by at least one parent scoring 36 or greater on the 25 item subscale of the Wender Utah Rating Scale (WURS). A 25-item subscale is present in which a cutoff score of 36 or greater is 96% sensitive and specific for a retrospective diagnosis of childhood ADHD in a parent. 17 In all, 30% of the parents have a history of ADHD.
A total of 179 children and their families took part in the study. Of these, 144 (80.3%) met research criteria for ICD-10 Hyperkinetic Disorder (HKD) or DSM-IV ADHD (combined, inattentive or hyperactiveimpulsive subtype). Of all, 36 (20.2%) had a clinical diagnosis of ADHD but failed to meet research criteria for ADHD due to lack of information, usually on pervasiveness. These 'subthreshold' cases were deemed to be informative for genetic studies on clinical traits within the ADHD diagnosis and were included in all analyses (except for the DSM-IV diagnostic subtypes) in this paper. With regard to DSM-IV ADHD, 112 children (62.6%) met research criteria for ADHD combined type, 21 (11.7%) for ADHD inattentive type and 11 (6.1%) for ADHD hyperactive-impulsive type. From the total of 179, 87 children (48.6%) met the criteria for ODD, 30 children (16.8%) met the criteria for CD and 91 children (50.8%) had one or more parents with a positive history of ADHD.
Genotyping
Genomic DNA was extracted from whole blood using a standard phenol/chloroform method or from buccal cells as described in Gill et al. 18 PCR amplification of the examined markers was carried out in a 12.5 ml reaction using 1 Â PCR reaction buffer containing 10 mM of Tris-HCl (pH 8.9), 30 ng of genomic DNA, 20 pmol of each primer, 200 ml of each dNTP and 0.5 U of Taq polymerase. Amplification and cycling conditions are given in Table 1 . Genotyping of all SNPs was performed using the SNaPshot Methodt (Applied Biosystems) as described in Norton et al. 19 This involves extending unlabelled primers by a single base using fluorescently tagged ddNTP's. Each of the four bases is labelled with a different coloured fluorescent dye that can be detected when run on an ABI Genetic Analyser (ABI PRISM 3100 genetic analyzer).
Statistical analysis
The transmission disequilibrium test (TDT) 20 was used to examine the association between the examined SNPs and ADHD. Linkage disequilibrium (LD, measured as D 0 ) between the SNPs was calculated using the program GOLD (www.well.ox.ac.uk/ asthma/GOLD). Haplotype analysis to test for the TPH2 gene variants associated with ADHD K Sheehan et al transmission of multilocus haplotypes was conducted using the program TRANSMIT (www.hgmp.mrc. ac.uk/Menu/transmit.html). This program tests the association between genetic markers and disease by examining the transmission from parents to affected children. All w 2 statistics and P-values are presented without correction for multiple testing.
Results
Genotypic distribution for all examined markers does not significantly differ from those expected according to Hardy-Weinburg equilibrium. In addition, allele frequencies calculated from parents with no history of ADHD show comparable frequencies to those reported for Caucasian populations. 21, 22 TDT analysis of the eight examined SNPs is presented in Table 2 . A highly significant association between the T allele of marker rs1843809 and ADHD was observed (w 2 ¼ 12.2, P ¼ 0.0006, OR ¼ 2.36). A similar but weaker association was also observed with marker rs1386497
In addition, increased transmission of allele C of marker rs1386493 was also observed but did not attain significance at Po0.05. Stratifying data by the sex of the transmitting parent (Tables 3 and 4) showed that the association between rs1843809 and ADHD is enhanced when paternal transmission alone is considered (w 2 ¼ 10.9, P ¼ 0.001, OR ¼ 3.7). Furthermore, the trend towards association of allele C of rs1386493 and allele A of rs1487279 in the total sample was stronger for paternal transmissions and attained significance at w 2 ¼ 4.6, P ¼ 0.04, OR ¼ 1.9 and w 2 ¼ 5. In all, 241 parents (70%) have no history of ADHD while 95 are history positive (30%) for the disorder. TDT analysis by family history for ADHD shows more transmission of the associated allele of marker rs1843809 from parents with a history of ADHD, Figure 1 Shows marker-to-marker D 0 relation of the examined TPH2 SNPs.
TPH2 gene variants associated with ADHD K Sheehan et al although this did not reach significance (transmitted 14 vs not transmitted 5, w 2 ¼ 4.26, P ¼ 0.064). In contrast, a significant association was observed when the transmission from the parent with no history of ADHD was considered (transmitted 36 vs not transmitted 13, w 2 ¼ 10.8, P ¼ 0.0014). TDT analysis of cases with comorbid ODD shows a significant association with the marker rs1843809 (transmitted 25 vs not transmitted 10, w 2 ¼ 6.43, P ¼ 0.016, OR ¼ 2.5). In contrast, no distortion in the transmission of any of the examined markers was observed when analyses were restricted to families with comorbid CD (transmitted 7 vs not transmitted 6).
Discussion
A highly significant overtransmission of allele T of marker rs1843809 to ADHD cases was observed (w 2 ¼ 12. 2, P ¼ 0.0006, OR ¼ 2.36). Several haplotypes made up of markers including rs1843809 are overrepresented in the ADHD cases. These findings indicate the importance of TPH2 as a potential susceptibility locus for ADHD.
Impulsive and aggressive behaviours are frequently associated with ADHD, which is associated with a reduction in serotonergic function. 7 Relatively low platelet serotonin levels have been reported in patients with ADHD. 23 TPH is a rate-limiting enzyme in the synthesis of serotonin from tryptophan. It is reasonable to hypothesise that genetic abnormalities in this gene may influence the concentration of brain serotonin levels and contribute to the development of many psychiatric disorders including ADHD.
The examined markers of the study are all intronic covering the gene with an average of B7-10 kb except between markers rs1386493 and rs1023990, where the physical distance is B26 kb. It is unlikely, therefore, that these markers would have a profound effect on the gene expression or protein structure as introns are spliced out during mRNA processing. Having said this, recent studies are suggesting the potential effect of intronic sequences. 24 If, however, the association of ADHD with rs1843809 of TPH2 is confirmed, it may represent LD with another variant that predisposes to ADHD. This presumptive causative variant would likely be located in the control or the coding regions of the gene. In support of our findings, Zill et al 21 have recently reported a significant association between TPH2 polymorphisms and major depression (MD). Interestingly, the rs1843809 T variant, which is most significantly associated with ADHD, is also associated with MD though this association did not remain significant after Bonferroni correction. In addition, the second TPH2 variant associated with MD (rs1386494) is located to intron 5, where the ADHD association maps. Furthermore, the two variants were found to be in significant LD (D 0 ¼ 0.63, P ¼ 0.01) in a Caucasian sample.
21
TPH2 is a member of an aromatic amino acid (aa) hydroxylase family that includes phenylalanine hydroxylase (PH) and tyrosine hydroxylase (TH). These enzymes are composed of an amino-terminal regulatory domain and a carboxyl-terminal catalytic domain. The carboxyl terminal of these enzymes is predicted to form two-thirds of the protein. A conserved five aa domain (Val, Pro, Trp, Phe, Pro) is present in all these enzymes, which serves to delineate the boundaries between the regulatory and catalytic domains. DNA and aa sequences map this motif to aa 105-109 and aa 151-156 for TPH1 and TPH2, respectively. Deletion of the first 106 aa in TPH1 had no effect on enzyme activity, but deletion of the first 116 aa (including those between 105 and 109) was found to abolish the enzyme activity demonstrating the importance of the region between residues 106 and 116 for TPH1 function. 25 It is plausible that DNA modification at the corresponding region in TPH2 (including aa 151-156) may influence the activity of the TPH2 enzyme consequently affecting the level of serotonin synthesis, a low level of which is thought to be correlated with ADHD. DNA sequence analysis shows that this motif maps to exon 4 of the TPH2 gene. 26 It is important therefore to fine map the boundaries of the ADHD-associated region particularly the coding and the exon-intron boundaries sequences.
The carboxyl-terminal catalytic domain is also essential for protein function; a recent study 27 demonstrated that the C1473G substitution (in mice) at the TPH2 gene results in Pro447Arg change. This has resulted in a 50 and 70% reduction in the levels of 5-HT synthesis in the frontal cortex and striatum, respectively, for the mice homozygous for the 1473G allele (Arg 447 ) compared to mice homozygous for the 1473C allele (Pro 447 ). This has emphasised the importance of the TPH2 gene in the aetiology of ADHD as these brain regions form the neural substrate of an anterior attentional system that is responsible for maintaining alertness and exercising attentional control. 28, 29 Transmission of some genetic conditions has been found to depend on the sex of the parent from whom the condition is inherited. The association of allele T of marker rs1843809 and ADHD was enhanced when paternal transmission alone was considered (OR ¼ 3.7). Paternal overtransmission of susceptibility alleles to ADHD cases is not confined to this gene. Overtransmission of alleles of paternal origin has been observed in our families for other associated genes such as DAT1, DRD4 and DRD5 (Hawi et al, in preparation). This parent of origin effect, one explanation for which is genomic imprinting (chromosomal modification of the germ line that leads to preferential expression of one of the two parental alleles in a parent of origin specific manner), 30 will be discussed elsewhere. In addition, TDT analysis by family history for ADHD shows a significant association of the marker rs1843809 in the families with no history of the disorder, whereas a trend in the same direction was seen in the case of families positive for ADHD. This can be attributed to the small number of transmissions, as the number of parents with a history of ADHD constitutes only 30% in this sample. Furthermore, although the association of rs1843809 and ADHD with comorbid ODD was also seen, it was considerably reduced. This may indicate that the association is primarily with ADHD rather than with ODD. A bigger sample is required to confirm or refute these speculations.
Finally, it is important to emphasise that future work requires examining the putative promoter region, exonic DNA variants and exon/intronic boundaries to determine if any of these variants are functional and what possible functional role DNA variants might have in the development of ADHD.
